



Figure S1. Flowchart of patient enrollment. We enrolled 46 subjects initially. Ten of them dropped out before 3-month follow-up, and one before 6-month follow-up due to children's factors, parents' factors, poor efficacy, or death. Four subjects were excluded for incomplete EEG data. Thirty-one subjects were finally included in this study, of whom 17 were KDT responders and 14 were non-responders.

Table S1. Patients' document. The clinical raw data of responders and non-responders were listed in this table. The six months seizure frequency means the average frequency during the first 6 months of ketogenic diet therapy. The six months seizure reduction rate (%) = (Baseline seizure frequency – six months seizure frequency) / Baseline seizure frequency x 100%. Responders were those who achieved a six months seizure reduction rate of 50% or more.

Age (Y; M)	Gender	Main Seizure type (ILAE 2017)	Etiology	Baseline Number of AEDs	Baseline Seizure Frequency (per month)	Six months Seizure Frequency (per month)	Six months Seizure Reduction rate (%)
13; 6	F	Focal to bilateral tonic-clonic	genetic	1	1	0	100.00
0; 9	M	Generalized onset, Motor	HIE	2	5	0	96.67
2; 4	M	Generalized onset, Motor	HIE	4	476	145	69.64
15; 4	F	1. Focal onset, Impaired awareness, Non-motor onset 2. Focal to bilateral tonic-clonic	unknown	4	1	0	100.00
6; 10	F	Focal onset, Impaired awareness, Non-motor onset	genetic	2	15	0	98.89
2; 6	M	Generalized onset, Motor	HIE	3	252	31	87.63
10; 3	M	Focal to bilateral tonic-clonic	unknown	3	224	33	85.12
3; 0	M	Generalized onset, Motor	genetic	3	224	19	91.59
1; 2	M	Generalized onset, Motor	structural	3	168	28	83.23
2; 4	F	1. Generalized onset, Motor 2. Focal to bilateral tonic-clonic	genetic	2	8	4	50.00
13; 10	F	Generalized onset, Motor	genetic	2	4	1	75.00
0; 10	F	1. Focal to bilateral tonic-clonic 2. Focal onset, Impaired awareness, Non-motor onset	genetic	4	3	1	77.78
4; 11	F	Generalized onset, Motor	unknown	3	196	88	55.10
15; 1	F	Focal to bilateral tonic-clonic	unknown	2	1	0	66.67
13; 10	F	Focal onset, Impaired awareness, Non-motor onset	genetic	2	6	2	72.22
4; 4	M	1. Focal onset, Impaired awareness, Non-motor onset 2. Focal onset, Impaired awareness, Motor onset	unknown	2	9	2	77.78
2; 11	M	Generalized onset, Motor	HIE	5	168	0	100.00
19; 1	M	Generalized onset, Motor	HIE	2	1	2	-83.33
14; 4	M	1. Focal onset, Impaired awareness, Motor onset 2. Focal to bilateral tonic-clonic	immune	3	33	19	43.94
10; 10	M	Generalized onset, Motor	unknown	2	1	1	-33.33

13; 2	F	Generalized onset, Motor	unknown	2	280	222	20.83
10; 0	M	1. Generalized onset, Nonmotor	genetic	2	32	18	44.79
		2. Generalized onset, Motor					
		3. Focal to bilateral tonic-clonic					
1; 2	M	Generalized onset, Motor	genetic	2	70	37	46.90
0; 10	F	1. Focal onset, Impaired awareness, Motor	structural	4	30	80	-165.00
		2. Focal to bilateral tonic-clonic					
9; 7	F	Focal onset, Impaired awareness, Non-motor	infectious	3	1	2	-116.67
10; 4	F	Focal onset, Impaired awareness, Non-motor	genetic	3	66	58	12.37
0; 3	F	Generalized onset, Motor	structural	3	51	33	34.64
0; 3	F	Generalized onset, Motor	genetic	4	41	48	-17.07
6; 0	M	Focal to bilateral tonic-clonic	genetic	1	5	11	-123.33
6; 1	F	Generalized onset, Motor	genetic	6	140	200	-0.429
0; 9	M	Generalized onset, Motor	genetic	3	140	100	0.286

Y: year; M: month; F: Female; M: Male; ILAE: International League Against Epilepsy; AED: anti-epileptic drug; HIE: hypoxic ischemic encephalopathy.